Iterum Therapeutics (ITRM) Competitors $1.08 -0.04 (-3.57%) Closing price 04:00 PM EasternExtended Trading$1.08 +0.00 (+0.46%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITRM vs. PBYI, TARA, IKT, PRQR, TLSA, NKTX, LYEL, SCPH, LRMR, and CTNMShould you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include Puma Biotechnology (PBYI), Protara Therapeutics (TARA), Inhibikase Therapeutics (IKT), ProQR Therapeutics (PRQR), Tiziana Life Sciences (TLSA), Nkarta (NKTX), Lyell Immunopharma (LYEL), scPharmaceuticals (SCPH), Larimar Therapeutics (LRMR), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry. Iterum Therapeutics vs. Puma Biotechnology Protara Therapeutics Inhibikase Therapeutics ProQR Therapeutics Tiziana Life Sciences Nkarta Lyell Immunopharma scPharmaceuticals Larimar Therapeutics Contineum Therapeutics Iterum Therapeutics (NASDAQ:ITRM) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings, community ranking and profitability. Does the media refer more to ITRM or PBYI? In the previous week, Puma Biotechnology had 3 more articles in the media than Iterum Therapeutics. MarketBeat recorded 8 mentions for Puma Biotechnology and 5 mentions for Iterum Therapeutics. Iterum Therapeutics' average media sentiment score of 0.97 beat Puma Biotechnology's score of 0.42 indicating that Iterum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iterum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, ITRM or PBYI? Iterum Therapeutics has a beta of 2.87, meaning that its share price is 187% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Do analysts rate ITRM or PBYI? Iterum Therapeutics currently has a consensus price target of $5.00, indicating a potential upside of 358.72%. Puma Biotechnology has a consensus price target of $7.00, indicating a potential upside of 122.58%. Given Iterum Therapeutics' higher probable upside, equities research analysts plainly believe Iterum Therapeutics is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, ITRM or PBYI? Puma Biotechnology has higher revenue and earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIterum TherapeuticsN/AN/A-$24.77M-$1.31-0.83Puma Biotechnology$230.47M0.68$21.59M$0.615.16 Does the MarketBeat Community believe in ITRM or PBYI? Puma Biotechnology received 415 more outperform votes than Iterum Therapeutics when rated by MarketBeat users. Likewise, 67.31% of users gave Puma Biotechnology an outperform vote while only 62.95% of users gave Iterum Therapeutics an outperform vote. CompanyUnderperformOutperformIterum TherapeuticsOutperform Votes14162.95% Underperform Votes8337.05% Puma BiotechnologyOutperform Votes55667.31% Underperform Votes27032.69% Do institutionals & insiders hold more shares of ITRM or PBYI? 9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 9.2% of Iterum Therapeutics shares are held by company insiders. Comparatively, 23.7% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is ITRM or PBYI more profitable? Puma Biotechnology has a net margin of 9.56% compared to Iterum Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat Iterum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Iterum TherapeuticsN/A N/A -90.85% Puma Biotechnology 9.56%41.60%10.71% SummaryPuma Biotechnology beats Iterum Therapeutics on 12 of the 15 factors compared between the two stocks. Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITRM vs. The Competition Export to ExcelMetricIterum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.69M$6.75B$5.51B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.837.3222.5518.49Price / SalesN/A239.19394.97102.66Price / CashN/A65.8538.1834.62Price / Book-9.086.436.694.25Net Income-$24.77M$143.21M$3.22B$248.31M7 Day Performance-16.15%1.24%1.11%1.12%1 Month Performance-6.84%6.09%3.59%3.68%1 Year Performance-31.45%-3.34%15.65%5.19% Iterum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITRMIterum Therapeutics2.5113 of 5 stars$1.08-3.6%$5.00+363.0%-26.8%$37.35MN/A-0.8210Short Interest ↓News CoveragePBYIPuma Biotechnology3.818 of 5 stars$2.86flat$7.00+144.8%-37.3%$141.89M$230.47M5.96200Upcoming EarningsAnalyst RevisionNews CoverageTARAProtara Therapeutics2.2488 of 5 stars$3.85-1.3%$20.40+429.9%+17.4%$141.55MN/A-1.3730Analyst ForecastNews CoverageIKTInhibikase Therapeutics1.5483 of 5 stars$1.89-0.5%$6.50+243.9%+53.7%$140.51M$260,000.00-0.716News CoveragePositive NewsPRQRProQR Therapeutics2.9094 of 5 stars$1.32+15.8%$9.50+619.7%-14.4%$138.88M$18.91M-4.13180Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsTLSATiziana Life Sciences0.472 of 5 stars$1.13+5.6%N/A+110.0%$132.04MN/A0.008Short Interest ↑News CoverageNKTXNkarta2.8394 of 5 stars$1.85+2.2%$14.86+703.1%-68.3%$131.27MN/A-0.98140Upcoming EarningsPositive NewsLYELLyell Immunopharma3.4151 of 5 stars$0.44+0.9%$1.00+128.5%-78.1%$129.25M$61,000.00-0.55270Upcoming EarningsNews CoveragePositive NewsGap UpSCPHscPharmaceuticals3.7243 of 5 stars$2.56-0.4%$14.00+446.9%-43.0%$128.73M$36.33M-1.3530News CoveragePositive NewsLRMRLarimar Therapeutics1.7324 of 5 stars$2.01+5.2%$19.63+876.4%-61.5%$128.70MN/A-1.7530Earnings ReportUpcoming EarningsOptions VolumeNews CoverageGap UpCTNMContineum Therapeutics1.9983 of 5 stars$4.95+7.1%$24.80+401.0%-73.7%$128.07M$50M-1.0131News Coverage Related Companies and Tools Related Companies Puma Biotechnology Alternatives Protara Therapeutics Alternatives Inhibikase Therapeutics Alternatives ProQR Therapeutics Alternatives Tiziana Life Sciences Alternatives Nkarta Alternatives Lyell Immunopharma Alternatives scPharmaceuticals Alternatives Larimar Therapeutics Alternatives Contineum Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITRM) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ITRM Stock Free ITRM Stock Alerts